Cyclophosphamide-based combination therapies for autoimmunity.
about
Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features.Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.Occipital lobe gumma: a case report and review of the literature.The ethanol extract of the inner bark of Caesalpinia pyramidalis (Tul.) reduces urinary bladder damage during cyclophosphamide-induced cystitis in rats
P2860
Cyclophosphamide-based combination therapies for autoimmunity.
description
2008 nî lūn-bûn
@nan
2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
Cyclophosphamide-based combination therapies for autoimmunity.
@ast
Cyclophosphamide-based combination therapies for autoimmunity.
@en
Cyclophosphamide-based combination therapies for autoimmunity.
@nl
type
label
Cyclophosphamide-based combination therapies for autoimmunity.
@ast
Cyclophosphamide-based combination therapies for autoimmunity.
@en
Cyclophosphamide-based combination therapies for autoimmunity.
@nl
prefLabel
Cyclophosphamide-based combination therapies for autoimmunity.
@ast
Cyclophosphamide-based combination therapies for autoimmunity.
@en
Cyclophosphamide-based combination therapies for autoimmunity.
@nl
P2093
P1476
Cyclophosphamide-based combination therapies for autoimmunity.
@en
P2093
Luciano Rinaldi
Massimiliano Calabrese
Paola Perini
Paolo Gallo
P2888
P304
P356
10.1007/S10072-008-0947-9
P478
29 Suppl 2
P577
2008-09-01T00:00:00Z